Compare Manulife Financial Corporation (MFC) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Manulife Financial Corporation trades at $42.93 (market cap $71.31B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Manulife Financial Corporation is far larger — about 73.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Manulife Financial Corporation pays a 3.15% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manulife Financial Corporation for 120 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MFC | MRVI | |
|---|---|---|
Market Cap | $71.31B | $972.90M |
Volume | 1,535,090 | 4,325,710 |
Sector | Financials | Health |
52-Week High | $44.77 | $9.00 |
52-Week Low | $31.64 | $2.83 |
Typical Hold Time | 120 Days | 0 Days |
Enterprise Value | $66.58B | $1.08B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MFC trades at $43.10, up 0.56% today, with a neutral technical signal and bullish moving averages. Revenue grew to $53.01B in 2025, with a net income margin of 11.7% and a P/E of 16.73. Recent news includes a new Chief Marketing Officer appointment and strong institutional investments, such as Bank of America's $145.18 million stake.
The outlook is positive with analyst consensus at Buy (57.14%) and a price target of $34.24, though below the current price. Risks include competitive pressures and debt levels, but earnings beats and dividend payments support stability. Growth is driven by Asia expansion and reinsurance deals, yet valuation premiums may limit near-term upside.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
